Evogene Showcases ChemPass AI™ at BIO International Convention 2026 to Advance Drug Development

Evogene Ltd. (EVGN) is positioning itself prominently within the biotechnology and pharmaceutical landscapes through its participation in the upcoming BIO International Convention in San Diego from June 22-25, 2026. This event will see key representatives from Evogene, including President and CEO Ofer Haviv, Chief Development Officer Dr. Gabi Tarcic, and VP of Business Development Dr. Olga Nissan, showcasing the company’s groundbreaking advancements. A centerpiece of their presentation will be Dr. Tarcic’s discussion on the innovative ChemPass AI™, a system that enhances small-molecule discovery and drug optimization by navigating extensive chemical spaces. This technology is set to revolutionize how collaborations are formed with pharmaceutical and biotech firms, enabling the production of novel and potent small molecules that meet crucial pharmaceutical criteria.

Highlighting Strategic Partnerships and Innovations

The role of ChemPass AI™ in facilitating strategic partnerships is significant, as it aligns with Evogene's commitment to integrating scientific innovation with practical industry applications. The system's capabilities allow for exploring chemical permutations that can lead to the development of highly effective medicinal compounds. During the BIO International Convention, Evogene invites potential partners and stakeholders for one-on-one meetings, highlighting their proactive approach to fostering collaborations that can drive mutual success in drug development. Such initiatives underscore the company’s desire not only to advance its technological offering but also to establish networks that enhance its industry presence.

A Platform for Networking and Visibility

This convention represents a pivotal moment for Evogene to amplify its visibility within the biotech sector and engage with key players who share their vision for innovation in pharmaceutical science. As industry dynamics evolve, Evogene positions ChemPass AI™ at the forefront of its strategy, aiming to advance drug discovery processes through enhanced technological capabilities. With the presentation scheduled for June 23, 2026, at 2:00 PM PT in Theater 1, Evogene is poised to make a significant impact during this influential gathering, demonstrating its potential in leading pioneering advancements in drug optimization and small-molecule development.

Commitment to Collaboration and Transparency

In addition to their conference participation, Evogene is resolutely focused on leveraging its proprietary technologies for mutual advancements in partnership with other firms in the biotech field. For further details and inquiries regarding their initiatives, Evogene encourages stakeholders to visit their official website. This strengthens the company's commitment to transparency and collaboration, reinforcing their strategic goals and expectations around their AI-driven solutions.